Another immuno-oncology drug is set to soon be introduced to Korea.

According to industry sources, GSK Korea has applied for the approval of its PD-1 inhibitor ‘Jemperli (dostarlimab),’ and is undergoing discussions with relevant authorities.

If approved, Jemperli will become the third PD-1 inhibitor to be approved in Korea after ‘Opdivo (nivolumab),’ and ‘Keytruda (pembrolizumab).’

Unlike the other two drugs that started as a melanoma treatment, Jemperli was approved for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regime